Baxter International Inc
Weighing in with Boston Scientific’s 4Q15 Revenues
Boston Scientific reported its 4Q15 earnings on February 4 and registered adjusted EPS of $0.26 in 4Q15, which represents 18% YoY growth.
Becton, Dickinson and Company’s 4Q16 Earnings Estimates
Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.
Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results
On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.
Inside Abiomed’s Profit Margin Expectations for Fiscal 2018
For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.
How Are Stryker’s Core Strategies Working Toward Its Growth?
Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.
Abbott Laboratories’ Stock Performance after a Recent Bull Run
On February 16, Abbott Laboratories (ABT) closed trading at $60.17 per share.
Investment-Grade Bond Funds Saw Outflows Last Week
Flows into investment-grade bond funds (LQD) were negative in the week ending June 17. This was the second consecutive week witnessing outflows.
S&P 500 Index Nears Record High amid Earnings Season
The S&P 500 Index, represented by the SPDR S&P 500 ETF (SPY), rose 0.3% on October 23, nearing the all-time high it saw in July.
Baxter Exhibits Strong 1Q16 Performance, Beat Estimates
On April 26, 2016, Baxter International (BAX) released its 1Q16 earnings. After the announcement, Baxter’s share price rose ~1% from $43.63 on April 25, 2016, due to the company’s better-than-expected 1Q16 results.
Effect of Claris Injectables Acquisition on Baxter’s 2017 Growth
On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.
Issuance of Investment-Grade Corporate Bonds Fell Last Week
Baxalta, Energy Transfer Partners, JPMorgan Chase, Occidental Petroleum, and Cardinal Health were among the biggest issuers of investment-grade corporate bonds last week.
Can Edwards Lifesciences See Robust Net Profit Margin in 2017?
In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.
Dan Loeb’s Third Point Looks to Baxter and Campbell Soup in 2019
During Q4 2018, Third Point reduced its stake by ~33% in healthcare company Baxter International (BAX).
Dan Loeb Increased Third Point’s Position in These Stocks in Q4
In Q4 2018, Third Point initiated a new position in Cigna (CI), which is an American healthcare services organization.
What Are Abbott Laboratories’ Key Growth Drivers in 2019?
On its fourth-quarter earnings call, Abbott forecast that its Established Pharmaceuticals segment would grow in the mid- to high single digits YoY in the first quarter.
GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth
As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity.
Baxter International: Why Investors Are Interested
Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018.
What Analysts Recommend for Stryker Stock
Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.
ABT Stock Registered a 52-Week High in October
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.
Abbott Laboratories Stock Trades at Its 52-Week High in September
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.
Baxter’s Global Business Units Continue to Deliver
Baxter International’s (BAX) global business units delivered strong performances in the second quarter.
How Baxter International Fared in the Second Quarter
Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.
How Wall Street Analysts View TransEnterix
Of the five analysts tracking TransEnterix in July, two of them have recommended a “strong buy,” and one has recommended a “buy.”
Analyst Recommendations for Boston Scientific and Peers in June
Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating.
How Much Upside Do Analysts See in Baxter Stock?
Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating.
A Close Look at Baxter International’s Acquisitions
Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018.
BAX May See Slight Rise in Net Profit Margins in Fiscal 2018
In 4Q17, Baxter International (BAX) reported adjusted earnings per share close to $0.64, which represents year-over-year growth of 12.0%.
Analysts’ March 2018 Ratings for Baxter International and Peers
In March, 17 analysts tracked Baxter International. Three gave a “strong buy” rating, seven gave a “buy” rating, and six suggested a “hold.”
Baxter International Completes Its Mallinckrodt Assets Buy
Baxter (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt for $185.0 million.
Why Abiomed’s Product Pipeline Looks Promising
Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps.
Rationale behind Varian Medical’s Acquisition of Sirtex Medical
On January 30, 2018, Varian Medical Systems (VAR) announced that it had entered into an agreement to acquire Sirtex Medical Limited for $1.3 billion.
Wall Street Issues Majority ‘Buy’ Ratings on Align Technology
On December 29, 2017, according to 12 investment brokerage firms which were part of a Reuters survey, Align Technology stock has received a “buy” rating from 11 analysts.
Baxter International Expected to Post Strong 4Q17 Results
Earnings results Baxter International (BAX) is expected to announce its 4Q17 and fiscal 2017 earnings results on or around January 30, 2018. The company announced stellar 3Q17 earnings results on October 25, 2017. Year-over-year, Baxter International expects to report 4Q17 sales growth of 4%–5% and constant-currency sales growth of ~2%. However, the company’s operational sales growth, expected […]
What’s Driving Baxter International’s Cash Flow Growth
Baxter International’s 2017 cash flow Between 9M16 (the first nine months of 2016) and 9M17, Baxter International’s (BAX) cash flow rose by $514 million to $933 million, exceeding its cash flow of $905 million in fiscal 2016. In fiscal 9M17, Baxter had operating cash flow of ~$1.3 billion, up $405 million from fiscal 9M16. In fiscal 2017, Baxter expects to […]
Discussing Baxter International’s Recent Stock Price Highs
On January 4, 2018, Baxter International was trading at a 52-week high of $68.86 per share, ending the day at $68.41 per share.
How Emerging Markets Continue to be the Key Growth Driver for BD
Overview BD (BDX) has significantly diversified operations around the world. It has a diverse base in emerging markets such as Eastern Europe, Latin America, Africa, the Middle East, and certain Asia-Pacific countries. The company is focused on expanding its operations in these high-growth markets and is undertaking strategic initiatives in this regard. It is mainly focused […]
Baxter International’s Latest Guidance for Fiscal 2017
Baxter International’s sales growth guidance for fiscal 2017 is expected to be ~4% on a reported basis.
Chart in Focus: Baxter International’s Intralipid 20% Recall
On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.
Management Changes at Baxter International: What You Should Know
Baxter International (BAX) has been going through a cost transformation and reorganization process for some time. The initiative includes some leadership and management changes.
Inside Baxter International’s Stock Price Performance
On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.
EMEA and APAC: Fresenius Medical Care’s Dialysis Products Business
In 1H17, Fresenius Medical Care (FMS) earned ~1.6 billion euros from the sale of dialysis products, which equals year-over-year growth of 8% on a reported basis.
Abiomed Expects to Expand Its Presence in This Space
Abiomed is primarily focused on the growth opportunity in the protected PCI area, a procedure that is applicable for patients with coronary artery disease.
Abiomed in 2017: The Analysts’ View
For the quarter ending March 31, 2017, Abiomed (ABMD) reported revenues close to $124.7 million, which represents a YoY growth of about 30%.
Behind Thermo Fisher’s Recent Stock Performance
TMO stock was trading at $173.2 on May 30, 2017. The stock had a 50-day moving average of $165.9 and a 200-day moving average of $153.8 that day.
Understanding Thermo Fisher’s Capital Deployment Strategy
Thermo Fisher Scientific expects to deploy 60%–75% of its capital toward M&As (mergers and acquisitions).
Understanding Thermo Fisher’s Growth Strategy
Thermo Fisher Scientific (TMO) has always focused on innovation as a key growth strategy.
How Is Mylan’s Generics Segment Doing?
Mylan’s (MYL) 3Q16 revenues were mainly driven by a 17.0% rise in sales for its Generics segment. The segment reported $2.6 billion in sales in 3Q16.
Analyzing Zimmer Biomet Holdings’ Financial Guidance for 2016
Zimmer Biomet revised its 2016 guidance after reporting its 3Q16 earnings. Its guidance for fiscal 2016 is estimated to be $7.63 billion–$7.65 billion.
Financial Metrics of Baxter’s Acquisition of Claris Injectables
The injectables business of Claris Lifesciences comprises 70.0%–80.0% of its total sales. Claris plans to repatriate about 85.0% of the generated funds to its shareholders.
Baxter’s Latest Dividend and Share Repurchase Authorization
Baxter International (BAX) announced a quarterly cash dividend of $0.13 per share on November 8, 2016.
Boston Scientific’s 3Q16 Earnings Beat Analysts’ Estimates
Boston Scientific (BSX) reported its 3Q16 earnings on October 26, 2016. It registered adjusted EPS of $0.27 in 3Q16. It had ~12.5% YoY growth.
Baxter International’s Recent Product Launches and Partnerships
Baxter International’s R&D investments were around $150 million in 2Q16, which represents a YoY (year-over-year) increase of around 1%.
Becton Dickinson’s BD Medical Segment Sales in Fiscal 3Q16
Becton, Dickinson and Company, or BD (BDX), reported ~$3.2 billion in worldwide revenue in fiscal 3Q16. Of that, ~$2.2 billion was generated by BD Medical, a segment that contributed ~70% to BD’s total revenues.
How Innovation Is Driving Thermo Fisher Scientific’s Growth
Thermo Fisher Scientific now has more than 800,000 products in its portfolio and has an extensive product pipeline.
Understanding Thermo Fisher Scientific’s Financial Model
Thermo Fisher Scientific aims to deliver adjusted EPS in the range of $11.3–$12.2 by 2019. This represents a three-year CAGR of 12%–15%.
Profit Booking Leaves the iShares US Medical Devices ETF (IHI) in the Red
On May 19, markets declined, with the SPDR S&P 500 ETF dropping by 0.3% and the iShares US Medical Devices ETF (IHI) declining by 0.8%.
Baxter’s 1Q16 Profitability and 2016 Guidance
Baxter International (BAX) revised its 2016 guidance as the company reported a strong 1Q16. Sales guidance for the year is updated from the 2%–3% range to approximately 3%.
Inside IHI’s Large-Caps: Becton Dickinson Rose on Good 2Q16
Becton Dickinson (BDX) announced its 2Q16 earnings on May 5, 2016. Becton Dickinson closed at $160.43 and was trading above the 20-day moving average. The stock has risen 4.1% YTD.
Innovation Drove Baxter’s Hospital Products Sales in 1Q16
Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$1.5 billion was contributed by the company’s Hospital Products business.
The Shire-Baxalta Merger: A Look at the Details
Following news of the Shire-Baxalta merger, Baxalta’s share price rose and Shire’s share price fell.
IHI Large-Caps: Baxter Launches Mobile Health App in India
In a press release, Baxter International (BAX) announced that it has launched a new mobile app in India called Sisu Janani Seva. It’s also known as mHealth.
Strategic Initiatives Driving Baxter’s Margin Expansion Goal
Baxter witnessed a series of changes in 2015, including a change in management, operational structure, and the establishment of a new strategic framework.
Why Medtronic Is Diversifying beyond Medical Devices
Medtronic established a services and solutions growth vector as one of its core strategies. It contributed ~20 basis points to Medtronic’s growth in 3Q16.
Baxter’s Position in Emerging Markets—and the Potential Risks
Emerging market economies like China, Brazil, and Russia have been facing difficult conditions in 2016. Baxter has 25% of its operations in such markets.
How Baxter’s Biosciences Spin-off into Baxalta Improved Its Valuation
On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations.
How a Strong Product Portfolio Drives Thermo Fisher’s Valuations
Thermo Fisher Scientific (TMO) registered sales of $4.7 billion, representing year-over-year growth of 4% in 4Q15 and fiscal 2015 sales of ~$17 billion.
The Geographic Strategy of Thermo Fisher Scientific
Thermo Fisher Scientific is a global company, but the majority of its revenues are generated from the developed markets. The US is its largest market, generating ~48% of the company’s total revenues.
BD Life Sciences Sales Hit by Weak Diagnostics Segment
In 1Q16, BD’s growth in its preanalytical and biosciences segment drove the BD Life Sciences segment sales.
Thermo Fisher Scientific’s Laboratory Products and Services Segment
Thermo Fisher Scientific’s Laboratory Products and Services segment earned revenues of approximately $6.6 billion in 2014, representing organic growth of around 5%.
Analyzing Becton, Dickinson and Company’s Geographic Strategy
Becton, Dickinson and Company (BDX), or BD, has operations across the globe, with more than 50% of its 2015 revenues coming from international markets.
Becton, Dickinson and Company: A Leading Global Medical Device Company
Becton, Dickinson and Company, or BD, headquartered in Franklin Lakes, New Jersey, is one of the leading medical technology companies in the United States.
An Overview of Becton, Dickinson and Company’s Business Model
On October 1, 2015, BD underwent organizational restructuring to better align its business model to the strategic vision and goals of the company.
A Must-Read Overview of the Medical Device Industry
The US medical device market is projected to grow at a compound annual growth rate of 6.1% between 2014 and 2017.
Novo Nordisk’s Hemophilia and Growth Disorder Research
In April 2015, Novo Nordisk (NVO) announced positive results from a Phase 3 clinical trial of N8-GP (turoctocog alfa pegol), a hemophilia drug.
Novo Nordisk Plans to Pursue Leadership in Hemophilia Market
Novo Nordisk is pursuing leadership in the hemophilia market with its new drugs as well as a few investigational hemophilia drugs in its late-stage research pipeline.
XLV Gained 1% as 60% of Portfolio Ended Positively for the Day
XLV outperformed the broader market representative SPDR S&P 50 ETF on October 1, 2015. SPY rose by 0.26% , compared with XLV’s 1.01%.
The Biotech Sector Is in a Downward Long-Term Trend
Though most of the biotech stocks rebounded from the recent lows, the long-term trend for biotech seems to be heading downward.
Understanding Leverage for Abbott Laboratories
Abbott Laboratories (ABT) uses both equity and debt for its working capital requirements as well as investments in the business.
Must-know: Insurance exchanges will affect medical device stocks
Big change to come in the healthcare industry Ready or not, state-run insurance exchanges will be ready for open enrollment starting October 1. The introduction of these public exchanges for individuals and small group employers highlights a significant change in the healthcare industry. Making consumer access to healthcare easier, more than 30 million people are […]